- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
The Mainstream Patient: May 31
Author(s):
This week's edition of the Mainstream Patients features stories about heat rash, drinking Aloe Vera juice, and more.
In this week’s edition, Self dives into a topic on the mind during the summer, heat rash, and InStyle talks the differents between toner and essence. Cosmopolitan lists the best under-eye treatments and Glamour talks the formula shortage. Elle explains hair toner and Allure discusses TikTok's trend of drinking Aloe Vera juice.
Here’s How to Get Rid of Heat Rash, According to Dermatologists
So, What's the Difference Between Toner and Essence Anyways?
12 Best Under-Eye Bag Treatments for Puffiness, According to Experts
‘Just Breastfeed’ Is the Worst Thing You Can Say to a Parent
Everything You Need To Know About Hair Toner
Why Is Everyone on TikTok Drinking Aloe Vera Juice?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
Key Takeaways on GEP Testing in Melanoma and SCC
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation
Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies
Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children
Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects
Overcoming Therapeutic Inertia in a 25-Year-Old Man with Moderate to Severe Atopic Dermatitis
Safety Considerations in Pediatric Atopic Dermatitis Treatments
Related Content
